Transneural Therapeutics Unveils Promising Preclinical Results for TN-001 at ACNP 2026 Transneural Therapeutics has presented encouraging preclinical data for their candidate TN-001, targeting neuropsychiatric disorders, at the ACNP 2026 meeting.

Transneural Therapeutics Unveils Promising Preclinical Results for TN-001 at ACNP 2026 #Bahamas #Nassau #Transneural_Therapeutics #Neuropsychiatric #TN-001

Transneural Therapeutics Appoints Renowned CNS Specialist to Lead Drug Development Efforts Transneural Therapeutics introduces Dr. Mark A. Demitrack as its new Chief Research and Development Officer, emphasizing his expertise in CNS drug development.

Transneural Therapeutics Appoints Renowned CNS Specialist to Lead Drug Development Efforts #USA #Seattle #CNS_Drug_Development #Transneural_Therapeutics #Mark_A._Demitrack